{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-028121","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.190122+00:00","generated_at":"2026-06-27T03:30:28.703902+00:00","sec_items":["3.01","5.02"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiora receives Nasdaq deficiency notice for bid price below $1.00; CFO resigns","bullets":["Nasdaq notified Kiora on Feb 23, 2022 that its stock closed below $1.00 for 30 consecutive business days.","Company has 180 days (until Aug 22, 2022) to regain compliance by closing >= $1.00 for at least 10 consecutive trading days.","CFO Sarah Romano resigned effective Feb 25, 2022; Corporate Controller Michael Meluzio appointed as principal financial and accounting officer.","Kiora evaluating options to regain compliance; may seek additional 180-day period if eligible."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-028121","json":"https://secwatch.observer/filing/0001104659-22-028121.json","markdown":"https://secwatch.observer/filing/0001104659-22-028121.md","text":"https://secwatch.observer/filing/0001104659-22-028121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/0001104659-22-028121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/tm227887d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:30:28.703902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57a6f7dc21","claim":"Sarah Romano resigned as Chief Financial Officer at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"Sarah Romano resigned as Chief Financial Officer of the Company effective as of February 25, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/0001104659-22-028121-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"efc9be552c","claim":"Michael Meluzio was appointed as principal financial officer and principal accounting officer at KIORA PHARMACEUTICALS INC.","evidence_excerpt":"the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/0001104659-22-028121-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}